UNSPSC 51262003: Azapetine

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TTR0UA2KC, chemically known as 6-allyl-6,7-dihydro-5h-dibenz(c,e)azepine but generally known as azapetine, which bears US NIH Compound Identifier 8966. azapetine most often comes in base, hydrochloride, and phosphate forms. European Medicines Agency schedules Azapetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12970MIG.

World Health Organization schedules azapetine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, AZAPETINE remains the US FDA Preferred Term for this commodity. Azapetine bears US NLM identifiers UMLS ID C0052752 and NCI Concept Code C83540. SMILES: N1(CC2C(C3C(C1)CCCC3)CCCC2)CC=C.

UNSPSC 51262003 Azapetine is a Commodity code that state and local procurement offices use to classify pharmaceutical products, though recent opportunities posted under this code show minimal alignment with the code's nominal scope. The two recent opportunities in the record involve naloxone procurement (a distinct opioid antagonist) and a pharmacy benefit management RFI rather than azapetine-specific purchases. State and local healthcare and public health agencies—including county health departments and state health commissions—are the primary issuing bodies visible in recent activity under this code, but the actual products being solicited diverge substantially from the code designation itself.

Activity is sparse and geographically limited. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program targeting self-insured employer and state agency health plans, designed to inform future formal procurement strategy. Neither opportunity directly reflects azapetine procurement. The code shows little relevant recent activity and may be misapplied to pharmaceutical category buys that fall more appropriately under broader drug or pharmacy benefit codes.